Compile Data Set for Download or QSAR
Report error Found 289 Enz. Inhib. hit(s) with all data for entry = 12688
TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719704(N-((5-(2-((2-methylquinazolin-4- yl)thio)acetyl)th...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719708(N-((5-(2-((2-methylpyrido[2,3- d]pyrimidin-4- yl)t...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719723(N-((5-(2-((2-methyl-6- (trifluoromethyl)-2H-pyrazo...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719731(N-((5-(2-((1-methyl-1H- pyrazolo[3,4-d]pyrimidin-4...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719736(N-(2-(5-(2-((2- (trifluoromethyl)quinazolin-4- yl)...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719738(N-((5-(2-((2- (trifluoromethyl)quinazolin-4- yl)th...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719741(N-((5-(2-((2-methyl-6- (trifluoromethyl)-2H-pyrazo...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719745(1-hydroxy-N-((5-(2-((5- (trifluoromethyl)oxazolo[4...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719746(3,3,3-trifluoro-2-hydroxy-N-((5-(2- ((2-methyl-6-(...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719748(2-hydroxy-2-methyl-N-((5-(2-((2- methyl-6-(trifluo...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719749(1-hydroxy-N-((5-(2-((2-methyl-6- (trifluoromethyl)...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719754(N-((5-(2-((1-methyl-1H- pyrazolo[3,4-d]pyrimidin-4...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719758(2-hydroxy-N-((5-(2-((6-methoxy-2- methylquinazolin...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719759(2-hydroxy-N-((5-(2-((2-methyl-6- (trifluoromethyl)...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719760(N-((5-(2-((2-ethylquinazolin-4- yl)thio)acetyl)thi...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719762(2-hydroxy-N-((5-(2-((2- methylpyrido[2,3-d]pyrimid...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719764(2-hydroxy-N-((5-(2-((2- methylquinazolin-4- yl)thi...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719769(2-hydroxy-N-((5-(2-((6- (trifluoromethyl)oxazolo[5...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719770(2-hydroxy-N-((5-(2-((5- (trifluoromethyl)oxazolo[4...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719771(N-((5-(2-((6-chloro-7-fluoro-2- methylquinazolin-4...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719772(2-hydroxy-N-((5-(2-((1-methyl-6- (trifluoromethyl)...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719774(2-hydroxy-N-((5-(2-((2-methyl-6- (trifluoromethyl)...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719775(N-((5-(2-((6-cyclopropoxy-2- methylquinazolin-4- y...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719776(N-((5-(2-((6- ((cyclopropylmethyl)amino)-2- methyl...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719777(N-((5-(2-((2-cyclopropyl-6- (trifluoromethyl)-2H-p...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719778(2-hydroxy-N-((5-(2-((6-methoxy-2- (trifluoromethyl...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719779(2-hydroxy-N-((5-(2-((2-methyl-6- morpholinoquinazo...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719780(2-hydroxy-N-((5-(2-((2-methyl-6- (piperidin-1-yl)q...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719781(2-hydroxy-N-((5-(2-((2-methyl-6- (1,4-oxazepan-4-y...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719782(N-((5-(2-((6-(3,3- difluoropyrrolidin-1-yl)-2- met...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719783(2-hydroxy-N-((5-(2-((2-methyl-6- (4-methylpiperazi...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719796(N-(2-(5-(2-((2- (trifluoromethyl)quinazolin-4- yl)...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719797(N-((5-(2-((2- (trifluoromethyl) quinazolin-4- yl)t...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719804(N-((5-(2-((6-cyclopropyl-2- methylquinazolin-4- yl...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719810(N-((5-(2-((7-cyclopropyl-2- (trifluoromethyl)pyraz...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719811(2-hydroxy-N-((5-(2-((2- (trifluoromethyl)pyrido[2,...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719812(2,2-difluoro-N-((5-(2-((2- (trifluoromethyl)pyrido...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719815(2-hydroxy-N-((5-(2-((5- (trifluoromethyl)oxazolo[5...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719816(2-hydroxy-N-((5-(2-((6- (trifluoromethyl)oxazolo[4...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719817(2-hydroxy-N-((5-(2-((2-methyl-6- (trifluoromethyl)...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719819(2-hydroxy-N-((5-(2-((6-methoxy- 2-methylpyrido[3,4...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719820(N-((5-(2-((2- (trifluoromethyl)pyrido[2,3- d]pyrim...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719821(2,2,2-trifluoro-N-((5-(2-((2- (trifluoromethyl)pyr...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719822(N-((5-(2-((6-fluoro-2- methylpyrido[2,3-d]pyrimidi...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719823(2-hydroxy-N-((5-(2-((1-(2- methoxyethyl)-6-(triflu...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719824(2-hydroxy-N-((5-(2-((2-methyl-6- (trifluoromethoxy...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719825(N-((5-(2-((2- (trifluoromethyl)pyrido[2,3- d]pyrim...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719827((S)-2-hydroxy-N-(1-(5-(2-((6- (trifluoromethyl)oxa...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719829(2-hydroxy-N-methyl-N-((5-(2-((2- (trifluoromethyl)...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

TargetHistone deacetylase 6 [482-800](Human)
Augustine Therapeutics

US Patent
LigandPNGBDBM719830(2-hydroxy-N-((5-(2-((2-(2- methoxyethyl)-6-(triflu...)
Affinity DataIC50: 100nMAssay Description:NanoBRET target engagement was performed against the catalytic domain 2 (CD2) of HDAC6, with minor modifications of kit manufacturer protocol (Promeg...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/17/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 289 total ) | Next | Last >>
Jump to: